Adjusting the starting dose of telaprevir according to renal function decreases adverse effects and affects the sustained virological response rate.

doi:10.1097/MEG.0000000000000208

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Community

Back to search

Article

Adjusting the starting dose of telaprevir according to renal function decreases adverse effects and affects the sustained virological response rate.

European journal of gastroenterology & hepatology - 1 Jan 2015

Morihara Daisuke, Watanabe Hiroshi, Takata Kazuhide, Iwashita Hideyuki, Tsuchiya Naoaki, Kunimoto Hideo, Kuno Shizuka, Fukunaga Atsushi, Yotsumoto Kaoru, Tanaka Takashi, Sakurai Kunitoshi, Hirano Genryu, Yokoyama Keiji, Nishizawa Shinya, Yoshikane Makoto, Anan Akira, Takeyama Yasuaki, Kitamura Yuji, Iwata Kaoru, Irie Makoto, Shakado Satoshi, Sohda Tetsuro, Sakisaka Shotaro

Abstract excerpt

BACKGROUND: Telaprevir (TVR) plays a major role in renal damage and anemia associated with TVR/pegylated interferon/ribavirin therapy for chronic hepatitis C. Adjusting the TVR starting dose may reduce these adverse effects. We aimed to determine whether adjusting the starting dose according to renal function reduces TVR-associated renal damage and anemia and affects the sustained virological response (SVR)....

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Acute Kidney Injury

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Anemia

Share to Drug Monitoring

Share to Glomerular Filtration Rate

Share to Hemoglobins

Share to Interferon alpha-2

Share to Oligopeptides

Share to Polyethylene Glycols

Source

Open in PubMed

Identifiers

PMID: 25370853
DOI: 10.1097/MEG.0000000000000208

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 6 Sept 2026. Manifest publication-graph-cohort-2026-09-06.1.

Source receipt: pubmed, retrieved 6 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Adjusting the starting dose of telaprevir according to renal function decreases adverse effects and affects the sustained virological response rate.PMID 25370853Read ↗

Clinical milestones for the prediction of severe anemia by chronic hepatitis C patients receiving telaprevir-based triple therapy.Semantic proximity Read ↗

[Clinical use of telaprevir: stopping rules, predicting response, treatment length, and management of adverse effects].Semantic proximity Read ↗

The prospective randomized study on telaprevir at 1500 or 2250 mg with pegylated interferon plus ribavirin in Japanese patients with HCV genotype 1.Semantic proximity Read ↗

Estimated glomerular filtration rate but not solute carrier polymorphisms influences anemia in HIV-hepatitis C virus coinfected patients treated with boceprevir or telaprevir-based therapy.Semantic proximity Read ↗

The dose-response relationship of peginterferon alfa-2a and ribavirin in the treatment of patients coinfected with HIV-HCV.Semantic proximity Read ↗

The real impact of telaprevir dosage on the antiviral and side effects of telaprevir, pegylated interferon and ribavirin therapy for chronic hepatitis C patients with HCV genotype 1.Semantic proximity Read ↗

Comparative safety study on severe anemia by simeprevir versus telaprevir-based triple therapy for chronic hepatitis C.Semantic proximity Read ↗

Effects of ribavirin dose reduction vs erythropoietin for boceprevir-related anemia in patients with chronic hepatitis C virus genotype 1 infection--a randomized trial.Semantic proximity Read ↗

Limited utility of ITPA deficiency to predict early anemia in HCV patients with advanced fibrosis receiving Telaprevir.Semantic proximity Read ↗

Telaprevir can be successfully and safely used to treat older patients with genotype 1b chronic hepatitis C.Semantic proximity Read ↗

Pretreatment serum levels of interferon-gamma-inducible protein-10 are associated with virologic response to telaprevir-based therapy.Semantic proximity Read ↗

Direct-acting antiviral-based triple therapy on alpha-fetoprotein level in chronic hepatitis C patients.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.